JP5755739B2 - β−アミロイド産生の減少のための化合物 - Google Patents
β−アミロイド産生の減少のための化合物 Download PDFInfo
- Publication number
- JP5755739B2 JP5755739B2 JP2013519760A JP2013519760A JP5755739B2 JP 5755739 B2 JP5755739 B2 JP 5755739B2 JP 2013519760 A JP2013519760 A JP 2013519760A JP 2013519760 A JP2013519760 A JP 2013519760A JP 5755739 B2 JP5755739 B2 JP 5755739B2
- Authority
- JP
- Japan
- Prior art keywords
- cyclopenta
- methyl
- azeno
- metheno
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C*=CNCCC=C(CCOC)N=C Chemical compound C*=CNCCC=C(CCOC)N=C 0.000 description 14
- WLDOLJNCTMUFFB-JLZUIIAYSA-N C/C=[N+](\c(cc1)cc(OCCBr)c1C#N)/[O-] Chemical compound C/C=[N+](\c(cc1)cc(OCCBr)c1C#N)/[O-] WLDOLJNCTMUFFB-JLZUIIAYSA-N 0.000 description 1
- UQYQBXPFBBZOCA-UHFFFAOYSA-N C=CCCNc1c(CCC2c3ccccc3)c2nc(Nc(cc2)cc(OCC=C)c2-[n]2cnc(C3C=C3)c2)n1 Chemical compound C=CCCNc1c(CCC2c3ccccc3)c2nc(Nc(cc2)cc(OCC=C)c2-[n]2cnc(C3C=C3)c2)n1 UQYQBXPFBBZOCA-UHFFFAOYSA-N 0.000 description 1
- HVTQTGVIIZNVHO-UHFFFAOYSA-N CC(C)(C)OC(NCCCCOc(cc(cc1)[N+]([O-])=O)c1N/C=N\C(\C)=N/C)=O Chemical compound CC(C)(C)OC(NCCCCOc(cc(cc1)[N+]([O-])=O)c1N/C=N\C(\C)=N/C)=O HVTQTGVIIZNVHO-UHFFFAOYSA-N 0.000 description 1
- GKTCRCZCZWHVNE-ARJAWSKDSA-N CN(C1)Cc2c(N(C)C/C=C\COc(cc(cc3)N4)c3C#N)nc4nc2C1c(cc1)ccc1F Chemical compound CN(C1)Cc2c(N(C)C/C=C\COc(cc(cc3)N4)c3C#N)nc4nc2C1c(cc1)ccc1F GKTCRCZCZWHVNE-ARJAWSKDSA-N 0.000 description 1
- VZPNBCNIDYHWME-UHFFFAOYSA-N CN(C1)Cc2c(NCCCCOc(cc(cc3)N4)c3C#N)nc4nc2C1c(cc1)ccc1F Chemical compound CN(C1)Cc2c(NCCCCOc(cc(cc3)N4)c3C#N)nc4nc2C1c(cc1)ccc1F VZPNBCNIDYHWME-UHFFFAOYSA-N 0.000 description 1
- LJSXWMIZZJBENZ-UHFFFAOYSA-N CN(CC(c(cc1)ccc1F)c1nc(Cl)n2)Cc1c2Cl Chemical compound CN(CC(c(cc1)ccc1F)c1nc(Cl)n2)Cc1c2Cl LJSXWMIZZJBENZ-UHFFFAOYSA-N 0.000 description 1
- RGBPEXFLCDGACP-UHFFFAOYSA-N CN(CC1c(cc2)ccc2F)CC(C(N2)=O)=C1NC2=O Chemical compound CN(CC1c(cc2)ccc2F)CC(C(N2)=O)=C1NC2=O RGBPEXFLCDGACP-UHFFFAOYSA-N 0.000 description 1
- SZWAGCIPFSMRIY-UHFFFAOYSA-N CNCCNc1c(CCC2c(cc3)ccc3F)c2nc(Cl)n1 Chemical compound CNCCNc1c(CCC2c(cc3)ccc3F)c2nc(Cl)n1 SZWAGCIPFSMRIY-UHFFFAOYSA-N 0.000 description 1
- CSVSKPNSMNFOQN-UHFFFAOYSA-N Cc(c(OCC=C)c1)ccc1[N+]([O-])=O Chemical compound Cc(c(OCC=C)c1)ccc1[N+]([O-])=O CSVSKPNSMNFOQN-UHFFFAOYSA-N 0.000 description 1
- RASJNMBLIHRANU-UHFFFAOYSA-N Cc(nc1)n[n]1-c(c(OCC=C)c1)ccc1N Chemical compound Cc(nc1)n[n]1-c(c(OCC=C)c1)ccc1N RASJNMBLIHRANU-UHFFFAOYSA-N 0.000 description 1
- QUTUBFXRMRBJTL-UHFFFAOYSA-N Cc(nc1)n[n]1-c(c(OCCCNC)c1)ccc1[N+]([O-])=O Chemical compound Cc(nc1)n[n]1-c(c(OCCCNC)c1)ccc1[N+]([O-])=O QUTUBFXRMRBJTL-UHFFFAOYSA-N 0.000 description 1
- BVELPMOCSOWMIL-UHFFFAOYSA-N Clc(nc1)c[n]1-c(c(OCCCCCCN1)c2)ccc2Nc2nc1c(CCC1c3ccccc3)c1n2 Chemical compound Clc(nc1)c[n]1-c(c(OCCCCCCN1)c2)ccc2Nc2nc1c(CCC1c3ccccc3)c1n2 BVELPMOCSOWMIL-UHFFFAOYSA-N 0.000 description 1
- QFEIITSWPXZAQX-UHFFFAOYSA-N Nc(cc1)cc(OCCCNc2c(CCC3c(c(F)c4)ccc4F)c3nc(Cl)n2)c1C#N Chemical compound Nc(cc1)cc(OCCCNc2c(CCC3c(c(F)c4)ccc4F)c3nc(Cl)n2)c1C#N QFEIITSWPXZAQX-UHFFFAOYSA-N 0.000 description 1
- ZZCNVYQOFJIREG-UHFFFAOYSA-N Nc(cc1)cc(OCCNCCNc2c(CCC3c(cc4)ccc4F)c3nc(Cl)n2)c1C#N Chemical compound Nc(cc1)cc(OCCNCCNc2c(CCC3c(cc4)ccc4F)c3nc(Cl)n2)c1C#N ZZCNVYQOFJIREG-UHFFFAOYSA-N 0.000 description 1
- JFXQCSMOTMZDAL-UHFFFAOYSA-N OCC(CCN(C(c1c2cccc1)=O)C2=O)O Chemical compound OCC(CCN(C(c1c2cccc1)=O)C2=O)O JFXQCSMOTMZDAL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36442510P | 2010-07-15 | 2010-07-15 | |
| US61/364,425 | 2010-07-15 | ||
| PCT/US2011/043628 WO2012009309A1 (en) | 2010-07-15 | 2011-07-12 | Compounds for the reduction of beta-amyloid production |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013531040A JP2013531040A (ja) | 2013-08-01 |
| JP2013531040A5 JP2013531040A5 (OSRAM) | 2014-08-07 |
| JP5755739B2 true JP5755739B2 (ja) | 2015-07-29 |
Family
ID=44511486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013519760A Expired - Fee Related JP5755739B2 (ja) | 2010-07-15 | 2011-07-12 | β−アミロイド産生の減少のための化合物 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8637523B2 (OSRAM) |
| EP (1) | EP2593461B1 (OSRAM) |
| JP (1) | JP5755739B2 (OSRAM) |
| KR (1) | KR20130041944A (OSRAM) |
| CN (1) | CN102971325B (OSRAM) |
| AR (1) | AR082241A1 (OSRAM) |
| AU (1) | AU2011279412B2 (OSRAM) |
| BR (1) | BR112013000920A2 (OSRAM) |
| CA (1) | CA2805294A1 (OSRAM) |
| CO (1) | CO6670589A2 (OSRAM) |
| EA (1) | EA021527B1 (OSRAM) |
| IL (1) | IL224202A (OSRAM) |
| MX (1) | MX2013000514A (OSRAM) |
| NZ (1) | NZ606950A (OSRAM) |
| SG (1) | SG186392A1 (OSRAM) |
| TW (1) | TW201206946A (OSRAM) |
| WO (1) | WO2012009309A1 (OSRAM) |
| ZA (1) | ZA201301178B (OSRAM) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0696663B2 (ja) | 1986-08-04 | 1994-11-30 | 東レ株式会社 | 樹脂組成物 |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| EP3495367B1 (en) | 2012-06-13 | 2020-09-30 | Incyte Holdings Corporation | Substituted tricyclic compounds as fgfr inhibitors |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| KR101473081B1 (ko) | 2013-01-25 | 2014-12-16 | 영남대학교 산학협력단 | 고리형 2-다이아조-1,3-다이카보닐 화합물을 출발물질로 하는 고리형 베타-엔아미노아마이드 유도체 및 우라실 유도체의 합성방법 |
| DK2986610T5 (en) | 2013-04-19 | 2018-12-10 | Incyte Holdings Corp | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS |
| CA2911259A1 (en) * | 2013-05-06 | 2014-11-13 | Merck Patent Gmbh | Macrocycles as kinase inhibitors |
| US9718805B2 (en) | 2013-06-04 | 2017-08-01 | Acturum Life Science AB | Triazole compounds and their use as gamma secretase modulators |
| ES2665421T3 (es) | 2013-06-04 | 2018-04-25 | Acturum Real Estate Ab | Compuestos de pirimidina y su uso como moduladores de la gamma secretasa |
| EP3004081B1 (en) | 2013-06-04 | 2017-11-15 | Acturum Real Estate AB | Triazole compounds and their use as gamma secretase modulators |
| WO2015153709A1 (en) * | 2014-04-02 | 2015-10-08 | Bristol-Myers Squibb Company | Difluoromethoxy compound with low bioactivation potential for the reduction of beta-amyloid production |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| CR20170390A (es) | 2015-02-20 | 2017-10-23 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de fgfr |
| EP3356373B1 (en) | 2015-09-29 | 2020-02-19 | Bayer Pharma Aktiengesellschaft | Novel macrocyclic sulfondiimine compounds |
| CN108368129B (zh) | 2015-10-08 | 2021-08-17 | 拜耳医药股份有限公司 | 改性大环化合物 |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| CA3057891A1 (en) | 2017-03-28 | 2018-10-04 | Bayer Aktiengesellschaft | Novel ptefb inhibiting macrocyclic compounds |
| US11254690B2 (en) | 2017-03-28 | 2022-02-22 | Bayer Pharma Aktiengesellschaft | PTEFb inhibiting macrocyclic compounds |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CN112566912A (zh) | 2018-05-04 | 2021-03-26 | 因赛特公司 | Fgfr抑制剂的盐 |
| US11466004B2 (en) | 2018-05-04 | 2022-10-11 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
| CN111471056B (zh) * | 2019-01-23 | 2021-07-02 | 成都先导药物开发股份有限公司 | 一种大环类免疫调节剂 |
| CN116023365B (zh) * | 2019-01-29 | 2025-02-14 | 轩竹生物科技股份有限公司 | 己酮糖激酶抑制剂及其用途 |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEAP202415945A (en) | 2019-10-14 | 2024-04-25 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| JP2024522189A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式ヘテロ環 |
| WO2022261159A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8143255B2 (en) * | 2005-11-16 | 2012-03-27 | S*Bio Pte Ltd. | Heteroalkyl linked pyrimidine derivatives |
| US7932261B2 (en) * | 2006-02-06 | 2011-04-26 | Janssen Pharmaceutica Nv | Macrocycle derivatives useful as inhibitors of β-secretase (BACE) |
| ITMI20061513A1 (it) | 2006-07-31 | 2008-02-01 | Poli Costruzione Materiali Trazione Spa | Unita' frenante compatta a disco per veicoli su rotaia |
| CA2707712A1 (en) * | 2007-12-06 | 2009-06-11 | Schering Corporation | Gamma secretase modulators |
| WO2009076352A1 (en) * | 2007-12-11 | 2009-06-18 | Schering Corporation | Gamma secretase modulators |
| BRPI0906799A2 (pt) * | 2008-01-11 | 2015-07-14 | Hoffmann La Roche | Moduladores para amiloide beta |
-
2011
- 2011-07-11 TW TW100124501A patent/TW201206946A/zh unknown
- 2011-07-12 MX MX2013000514A patent/MX2013000514A/es active IP Right Grant
- 2011-07-12 EP EP11746340.6A patent/EP2593461B1/en not_active Not-in-force
- 2011-07-12 BR BR112013000920A patent/BR112013000920A2/pt not_active IP Right Cessation
- 2011-07-12 SG SG2012093274A patent/SG186392A1/en unknown
- 2011-07-12 AU AU2011279412A patent/AU2011279412B2/en not_active Ceased
- 2011-07-12 CA CA2805294A patent/CA2805294A1/en not_active Abandoned
- 2011-07-12 US US13/180,623 patent/US8637523B2/en active Active
- 2011-07-12 WO PCT/US2011/043628 patent/WO2012009309A1/en not_active Ceased
- 2011-07-12 CN CN201180034655.5A patent/CN102971325B/zh not_active Expired - Fee Related
- 2011-07-12 JP JP2013519760A patent/JP5755739B2/ja not_active Expired - Fee Related
- 2011-07-12 NZ NZ606950A patent/NZ606950A/en not_active IP Right Cessation
- 2011-07-12 KR KR1020137003728A patent/KR20130041944A/ko not_active Withdrawn
- 2011-07-12 EA EA201270824A patent/EA021527B1/ru not_active IP Right Cessation
- 2011-07-15 AR ARP110102569A patent/AR082241A1/es not_active Application Discontinuation
-
2013
- 2013-01-13 IL IL224202A patent/IL224202A/en not_active IP Right Cessation
- 2013-02-11 CO CO13027683A patent/CO6670589A2/es active IP Right Grant
- 2013-02-14 ZA ZA2013/01178A patent/ZA201301178B/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0696663B2 (ja) | 1986-08-04 | 1994-11-30 | 東レ株式会社 | 樹脂組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102971325A (zh) | 2013-03-13 |
| KR20130041944A (ko) | 2013-04-25 |
| EA021527B1 (ru) | 2015-07-30 |
| CA2805294A1 (en) | 2012-01-19 |
| AU2011279412B2 (en) | 2014-12-11 |
| IL224202A (en) | 2016-04-21 |
| CN102971325B (zh) | 2016-01-20 |
| EP2593461B1 (en) | 2016-08-17 |
| JP2013531040A (ja) | 2013-08-01 |
| US20120184565A1 (en) | 2012-07-19 |
| ZA201301178B (en) | 2014-07-30 |
| EA201270824A1 (ru) | 2013-04-30 |
| NZ606950A (en) | 2014-08-29 |
| BR112013000920A2 (pt) | 2016-05-17 |
| SG186392A1 (en) | 2013-02-28 |
| US8637523B2 (en) | 2014-01-28 |
| AU2011279412A1 (en) | 2013-03-07 |
| TW201206946A (en) | 2012-02-16 |
| AR082241A1 (es) | 2012-11-21 |
| CO6670589A2 (es) | 2013-05-15 |
| MX2013000514A (es) | 2013-02-27 |
| WO2012009309A1 (en) | 2012-01-19 |
| EP2593461A1 (en) | 2013-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5755739B2 (ja) | β−アミロイド産生の減少のための化合物 | |
| TWI468402B (zh) | 降低β－類澱粉生成之化合物 | |
| US8637525B2 (en) | Compounds for the reduction of beta-amyloid production | |
| ES2426023T3 (es) | Compuestos bicíclicos para la reducción de producción de beta amiloide | |
| US8604024B2 (en) | Compounds for the reduction of beta-amyloid production | |
| JP5908499B2 (ja) | β−アミロイド産生を減少させるための化合物 | |
| WO2025024329A2 (en) | Compounds, compositions, and methods | |
| HK1164732B (en) | Compounds for the reduction of beta-amyloid production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140619 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140619 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150409 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150414 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150423 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150519 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150527 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5755739 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |